Disc Medicine Q2 EPS $(1.03) Beats $(1.11) Estimate
Portfolio Pulse from Benzinga Newsdesk
Disc Medicine (NASDAQ:IRON) reported a Q2 EPS loss of $(1.03), beating the analyst estimate of $(1.11) by 7.21%. This represents a 39.19% increase in losses compared to $(0.74) per share from the same period last year.
August 08, 2024 | 12:39 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Disc Medicine reported a Q2 EPS loss of $(1.03), which beat the analyst estimate of $(1.11) by 7.21%. However, the losses increased by 39.19% compared to the same period last year.
While Disc Medicine's Q2 EPS loss was better than expected, the significant year-over-year increase in losses may concern investors. The mixed results could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100